|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-2-14
|
|
pubmed:abstractText |
Bronchiolitis obliterans syndrome (BOS) is the major problem after lung and heart-lung transplantation (LTx/HLTx). Sirolimus (Sir) and Mycophenolate (MMF) showed a promising efficacy in the treatment of BOS in animal models. The first clinical experience in converting LTx/HLTx-recipients with BOS from calcineurin inhibitor-(CNI)-based immunosuppression to a Sir-MMF based immunosuppression is reported herein.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
81
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
355-60
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:16477220-Adolescent,
pubmed-meshheading:16477220-Adult,
pubmed-meshheading:16477220-Bronchiolitis Obliterans,
pubmed-meshheading:16477220-Calcineurin,
pubmed-meshheading:16477220-Disease Progression,
pubmed-meshheading:16477220-Female,
pubmed-meshheading:16477220-Graft Rejection,
pubmed-meshheading:16477220-Heart-Lung Transplantation,
pubmed-meshheading:16477220-Humans,
pubmed-meshheading:16477220-Immunosuppression,
pubmed-meshheading:16477220-Immunosuppressive Agents,
pubmed-meshheading:16477220-Kidney,
pubmed-meshheading:16477220-Lung Transplantation,
pubmed-meshheading:16477220-Male,
pubmed-meshheading:16477220-Middle Aged,
pubmed-meshheading:16477220-Mycophenolic Acid,
pubmed-meshheading:16477220-Sirolimus,
pubmed-meshheading:16477220-Syndrome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Conversion to sirolimus and mycophenolate can attenuate the progression of bronchiolitis obliterans syndrome and improves renal function after lung transplantation.
|
|
pubmed:affiliation |
Department of Cardiothoracic and Vascular Surgery, Friedrich Schiller University Hospital, Jena, Germany. jgroetzner@t-online.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
